Novel variant form corona virus first reported in South Africa and Brazil to be less efficiently inhibited by antibodies from recovered patients and vaccinated individuals, a new study confirms.
According to research published in the journal Cell, recovery from COVID-19 as well as vaccinations may only offer incomplete protection against this mutant form of the virus.
“This is worrying because the rapid spread of variants that may not be efficiently inhibited by antibodies could undermine our current vaccination strategy,” said Stefan Pohlmann, co-author of the study from the German Primate Center in Gottingen.
This viral variant has a mutation in the spike protein – a structure on the surface of the virus that is responsible for attaching to host cells – the researchers said.
In order for the virus to enter cells, they say it must first attach to the surface of the host cell using its spike protein, which is located in the viral envelope.
The spike protein is also a target for antibody therapy and vaccines aimed at preventing viral replication in the body, they added.
Based on the research, scientists say the antibodies used to treat COVID-19 do not inhibit South Africa and Brazil. corona virus variants – B.1.351 and P.1.
“In addition, these variants are poorly inhibited by the antibodies of cured or vaccinated individuals, they partially bypass the antibody neutralizing effect,” said Jan Munch, another study co-author.
The study noted that vaccination or recovery from COVID-19 could offer reduced protection from the SARS-CoV-2 variants B.1.351 and P.1.
“Our findings suggest that it is important to limit the spread of the virus as much as possible until vaccination is widely possible. Otherwise, we risk the emergence of new variants that cannot be effectively controlled by currently available vaccines,” said Markus Hoffmann, the study’s first author.
(Only the title and image of this report may have been reworked by Business Standards staff; other content was generated automatically from syndicated feeds.)